<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03654001</url>
  </required_header>
  <id_info>
    <org_study_id>RF-2016-02361583</org_study_id>
    <nct_id>NCT03654001</nct_id>
  </id_info>
  <brief_title>ALBumin Italian Outcome Septic Shock-BALANCED Trial (ALBIOSS-BALANCED)</brief_title>
  <acronym>ALBIOSS-BAL</acronym>
  <official_title>Efficacy of Albumin Replacement and Balanced Solution in Patients With Septic Shock (the ALBIOSS-BALANCED Trial): a 2-by-2 Factorial, Investigator-initiated, Open- Label, Multicenter, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Istituto Di Ricerche Farmacologiche Mario Negri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock is a devastating condition often observed in ICU. It is characterized by
      pro-inflammatory and immune responses, organ failures, high incidence of AKI and lethality.
      Fluid resuscitation is pivotal as supportive therapy. At present, there are no effective
      therapies to improve survival of such clinical condition, often characterized by a mortality
      as high as 40% during the first 90 days from diagnosis.

      This project proposes a large 2-by-2 factorial randomized clinical trial testing the efficacy
      of albumin and the low- chloride balanced crystalloid solutions (either Ringer Lactate,
      Ringer Acetate, or Crystalsol - BAL) in septic shock.

      The investigators have recently concluded a multicenter, randomized trial, the ALBIOS trial,
      in which, in a post-hoc analysis, albumin, in addition to crystalloids, reduced 90-day
      mortality in patients with septic shock, as compared to crystalloids alone (Caironi P et al,
      2014). Crystalloids with supra-physiological chloride content may deteriorate renal
      perfusion, increasing the risk of acute kidney injury (AKI) and mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The project will consist of a 2-by-2 factorial, investigator-initiated, open-label,
      multicenter, randomized, controlled trial, with PROBE design (Prospective Randomized Open
      Trial with Blinded Evaluation of Outcomes), in patients with septic shock, as defined
      according to clinical criteria.

      Patients will be randomized in a 1:1:1:1 ratio to one of the 4 study groups (Albumin + BAL,
      Albumin + NS, BAL, NS).

      Both the primary endpoints will include events evaluated objectively: 90-day mortality and
      incidence of AKI, as assessed by KDIGO criteria (KDIGO Acute Kidney Injury Work Group, 2012).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>2-by-2 factorial design, open-label, multicenter, randomized, controlled trial, in patients with septic shock, as defined according to clinical criteria. Patients will be randomized in a 1:1:1:1 ratio to one of the 4 groups (Albumin + BAL, Albumin + NS, BAL, NS).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause 90-day mortality</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>All-cause death from randomization to 90 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Combined co-primary endpoint</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>The composite of all-cause death from randomization to 90 days and new occurrence of acute kidney injury (AKI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>Up to ICU discharge, a median of 9 days</time_frame>
    <description>All-cause death occurring in Intensive Care Unit (ICU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>Up to hospital discharge, a median of 20 days</time_frame>
    <description>All-cause death occurring during hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year mortality</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>All-cause death from randomization to 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>Up to 90 days or ICU discharge - a median of 9 days - whichever comes first</time_frame>
    <description>Severity and incidence of organ failures, as assessed by the Sequential Organ Failure Assessment (SOFA) score. SOFA score is used to determine the extent of organ function in a patient while in the intensive care unit. The score is based on 6 different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems. The scale of each score ranges from 0 (no dysfunction) to 4 (maximal dysfunction). The 6 scores are then added up to provide a global score: the highest the value, the worst the condition of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AKI</measure>
    <time_frame>Up to 90 days or ICU discharge - a median of 9 days - whichever comes first</time_frame>
    <description>Assessed by the Kidney Disease Improving Global Outcome (KDIGO) criteria as any of the following: (1) increase in serum creatinine &gt;=0.3 mg/dl (26.5 mmol/l) within 48 hours; or (2) increase in SCr to &gt;=1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or (3) urine volume &lt;0.5 ml/kg/h for 6 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RRT</measure>
    <time_frame>Up to 90 days or ICU discharge - a median of 9 days - whichever comes first</time_frame>
    <description>First use of Renal Replacement Therapy (RRT) during ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for vasopressors</measure>
    <time_frame>Up to 90 days or ICU discharge - a median of 9 days - whichever comes first</time_frame>
    <description>Duration of the need for vasopressors during ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>Up to 90 days or ICU discharge - a median of 9 days - whichever comes first</time_frame>
    <description>Duration of mechanical ventilation during ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary infections in ICU</measure>
    <time_frame>Up to 90 days or ICU discharge - a median of 9 days - whichever comes first</time_frame>
    <description>Incidence of secondary-acquired infections during ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stay in ICU</measure>
    <time_frame>Up to ICU discharge, a median of 9 days</time_frame>
    <description>Duration expressed as number of days spent in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stay in hospital</measure>
    <time_frame>Up to hospital discharge, a median of 20 days</time_frame>
    <description>Duration expressed as number of days spent in hospital</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Severe metabolic acidosis</measure>
    <time_frame>Up to 90 days or ICU discharge - a median of 9 days - whichever comes first</time_frame>
    <description>Incidence of severe metabolic acidosis</description>
  </other_outcome>
  <other_outcome>
    <measure>Severe hyperkalemia</measure>
    <time_frame>Up to 90 days or ICU discharge - a median of 9 days - whichever comes first</time_frame>
    <description>Incidence of severe hyperkalemia</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1252</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Albumin + Balanced</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.
Balanced crystalloid solutions
According to the preference and the standard use of the participating center:
Ringer Lactate
Ringer Acetate
Crystalsol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albumin + Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.
Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Balanced</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Balanced crystalloid solutions (Ringer Lactate, Ringer Acetate, Crystalsol)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <description>Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.</description>
    <arm_group_label>Albumin + Balanced</arm_group_label>
    <arm_group_label>Albumin + Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Balanced</intervention_name>
    <description>Balanced crystalloid solutions are traditionally crystalloid solutions containing a relatively low concentration of chloride as compared to 0.9% NaCl containing solutions (Normal Saline).</description>
    <arm_group_label>Albumin + Balanced</arm_group_label>
    <arm_group_label>Balanced</arm_group_label>
    <other_name>Ringer Lactate, Ringer Acetate, Crystalsol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with septic shock if they meet the two following criteria:

          1. Presence of an infection (known or suspected) in at least one site:

               1. Lung

               2. Abdomen

               3. Urinary tract

               4. Others (blood, skin and soft tissues, central nervous system, bones and joints,
                  cardiac system, reproductive organs).

          2. Presence of a severe and acute, sepsis-related cardiovascular failure (as assessed by
             the SOFA score - see Annex 1), requiring vasopressor to maintain mean arterial
             pressure &gt;=65 mmHg, despite adequate volume resuscitation a) Cardiovascular SOFA score
             &gt; 2 (3 or 4) If the patient is unable to provide informed consent, she/he can be
             included in the trial provided that the requirements of ongoing laws are fulfilled;
             details on this approach are provided in the protocol, par 11.1 and related Annex 3.
             The patient will be informed about having been included in a clinical trial, as soon
             as she/he will regain consciousness.

        Exclusion Criteria:

          1. Age &lt; 18 years

          2. Moribund state

          3. Known or suspected adverse reaction to albumin administration

          4. Septic shock in patients with traumatic brain injury or a clinically active cerebral
             lesion (known or suspected)

          5. Severe congestive heart failure (NYHA III and IV classes)

          6. Clinical situations in which the use of albumin is known or supposed to be clinically
             beneficial (hepatic cirrhosis with ascites, malabsorption syndrome or protein-losing
             enteropathy, nephrotic syndrome, burns)

          7. More than 24 hours after the onset of septic shock

          8. Religious objection to the administration of human blood products

          9. Presence of chronic end-stage renal disease

         10. Severe hyperkalemia

         11. Enrollment in other experimental interventional studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pietro Caironi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOU S. Luigi Gonzaga, Orbassano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Pesenti, MD</last_name>
    <phone>+390255033231</phone>
    <email>antonio.pesenti@unimi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pietro Caironi, MD</last_name>
    <phone>+393316171966</phone>
    <email>pietro.caironi@unito.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedali Riuniti di Ancona</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abele Donati, MD</last_name>
      <phone>+39 071 596 4603</phone>
      <email>abele.donati@ospedaliriuniti.marche.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale Umberto Parini</name>
      <address>
        <city>Aosta</city>
        <state>AO</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Montagnani, MD</last_name>
      <phone>0165 543276</phone>
      <email>lmontagnani@ausl.vda.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico di Bari</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Salvatore Grasso, MD</last_name>
      <phone>0805592531</phone>
      <email>salvatore.grasso@uniba.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio Fabretti, MD</last_name>
      <phone>0352675162</phone>
      <email>ffabbretti@asst-hpg23.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST BG Est - Ospedale Bolognini</name>
      <address>
        <city>Seriate</city>
        <state>BG</state>
        <zip>24068</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Keim, MD</last_name>
      <phone>0353063270</phone>
      <email>roberto.keim@asst-bergamoest.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AST BG Ovest - PO Treviglio</name>
      <address>
        <city>Treviglio</city>
        <state>BG</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Massimo Borelli, MD</last_name>
      <phone>0363424230</phone>
      <email>massimo_borelli@asst-bgovest.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Siniscalchi, MD</last_name>
      <phone>051 2143268</phone>
      <email>antonio.siniscalchi@aosp.bo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Mater Domini Catanzaro</name>
      <address>
        <city>Catanzaro</city>
        <state>CZ</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Navalesi, MD</last_name>
      <phone>09613647047</phone>
      <email>pnavalesi@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria di Ferrara - Arcispedale Sant'Anna</name>
      <address>
        <city>Cona</city>
        <state>FE</state>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo Alberto Volta, MD</last_name>
      <phone>0532236451</phone>
      <email>vlc@unife.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Foggia</name>
      <address>
        <city>Foggia</city>
        <state>FG</state>
        <zip>71121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucia Mirabella, MD</last_name>
      <phone>0881732307</phone>
      <email>lucia.mirabella@unifg.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale del Mugello</name>
      <address>
        <city>Borgo San Lorenzo</city>
        <state>FI</state>
        <zip>50032</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vieri Parrini, MD</last_name>
      <phone>05584451310</phone>
      <email>vieri.parrini@uslcentro.tosca.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giuseppe</name>
      <address>
        <city>Empoli</city>
        <state>FI</state>
        <zip>50053</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Italo Calamai, MD</last_name>
      <phone>057 17051</phone>
      <email>italo.calamai@uslcentro.toscana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Careggi</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano Romagnoli, MD</last_name>
      <phone>055 0760007</phone>
      <email>stefano.romagnoli@unifi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni di Dio</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50143</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Oggioni, MD</last_name>
      <phone>055693478</phone>
      <email>roberto.oggioni@uslcentro.toscana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ente Ospedaliero Ospedali Galliera</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Lattuada, MD</last_name>
      <phone>01056231</phone>
      <email>marco.lattuada@galliera.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Pelosi, MD</last_name>
      <phone>0105554982</phone>
      <email>ppelosi@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Colline dell'Albegna</name>
      <address>
        <city>Orbetello</city>
        <state>GR</state>
        <zip>58045</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Pasetti, MD</last_name>
      <phone>05644869212</phone>
      <email>giovannistefano.pasetti@uslsudest.toscana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Lecco AO Manzoni</name>
      <address>
        <city>Lecco</city>
        <state>LC</state>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Tavola, MD</last_name>
      <phone>0341489984</phone>
      <email>ma.tavola@asst-lecco.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <state>LE</state>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniela Puscio, MD</last_name>
      <phone>0832 661111</phone>
      <email>daniela.puscio@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero di Desio</name>
      <address>
        <city>Desio</city>
        <state>MB</state>
        <zip>20039</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Citerio, MD</last_name>
      <phone>0362383213</phone>
      <email>giuseppe.citerio@unimib.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Foti, MD</last_name>
      <phone>0392339269</phone>
      <email>g.foti@asst-monza.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Nord Milano - Ospedale Bassini</name>
      <address>
        <city>Cinisello Balsamo</city>
        <state>MI</state>
        <zip>20092</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Buttini, MD</last_name>
      <phone>0257998271</phone>
      <email>stefano.muttini@asst-nordmilano.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Ovest Milano</name>
      <address>
        <city>Legnano</city>
        <state>MI</state>
        <zip>20025</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danilo Radrizzani, MD</last_name>
      <phone>0331449458</phone>
      <email>danilo.radrizzani@asst-ovestmi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Pesenti, MD</last_name>
      <phone>0255033230</phone>
      <email>antonio.pesenti@unimi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Santi Paolo e Carlo, Ospedale San Paolo, Polo Universitario</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Davide Chiumello, MD</last_name>
      <phone>0281844476</phone>
      <email>davide.chiumello@unimi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Fatebenefratelli - Sacco P.O. Sacco</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emanuele Catena, MD</last_name>
      <phone>0239043132</phone>
      <email>catena.emanuele@asst-fbt-sacco.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riccardo Pinciroli, MD</last_name>
      <phone>02644447235</phone>
      <email>riccardo.pinciroli@unimib.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>MI</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Ballotta, MD</last_name>
      <phone>0252774508</phone>
      <email>andrea.ballotta@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>MI</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Resta, MD</last_name>
      <phone>02527741</phone>
      <email>marco.resta@grupposandonato.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Modena, Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Girardis, MD</last_name>
      <phone>0594224813</phone>
      <email>girardis.massimo@unimo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cortigiani, MD</last_name>
      <phone>0916552738</phone>
      <email>cortegiani@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ISMETT</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Arcadipane, MD</last_name>
      <phone>0912192378</phone>
      <email>aarcadipane@ismett.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Persona, MD</last_name>
      <phone>0498212222</phone>
      <email>ppersona75@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Pisana</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabio Guarracino, MD</last_name>
      <phone>050995244</phone>
      <email>f.guarracino@ao-pisa.toscana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra Rossi, MD</last_name>
      <phone>0521703064</phone>
      <email>sarossi@ao.pr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giorgio Iotti, MD</last_name>
      <phone>0382503477</phone>
      <email>g.iotti@smatteo.pv.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS ASMN Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>43123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giorgio Danelli, MD</last_name>
      <phone>0522236599</phone>
      <email>danelli.giorgiofrancesco@ausl.re.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Massimo Antonelli, MD</last_name>
      <phone>0630154490</phone>
      <email>m.antonelli@rm.unicatt.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Sassari</name>
      <address>
        <city>Sassari</city>
        <state>SS</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierpaolo Terragni, MD</last_name>
      <phone>079228270</phone>
      <email>pterragni@uniss.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Chiara</name>
      <address>
        <city>Trento</city>
        <state>TN</state>
        <zip>38122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Cavana, MD</last_name>
      <email>marco.cavana@apss.tn.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce</name>
      <address>
        <city>Moncalieri</city>
        <state>TO</state>
        <zip>10024</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fiore Gilberto, MD</last_name>
      <phone>011 6930254</phone>
      <email>fiore.gilberto@aslto5.piemonte.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria S. Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <state>TO</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pietro Caironi, MD</last_name>
      <phone>0119026386</phone>
      <email>pietro.caironi@unito.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Brazzi, MD</last_name>
      <phone>0116335500</phone>
      <email>luca.brazzi@unito.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASL TO2 Ospedale S.G.Bosco</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10154</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergio Livigni</last_name>
      <phone>0112402402</phone>
      <email>sergio.livigni@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata di Udine</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiziana Bove, MD</last_name>
      <phone>0432 559501</phone>
      <email>clinicaanestesiarianimazione@asuiud.sanita.fvg.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Galmarini Tradate</name>
      <address>
        <city>Tradate</city>
        <state>VA</state>
        <zip>21049</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo Capra, MD</last_name>
      <phone>03311817917</phone>
      <email>carlo.capra@asst-settelaghi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <state>VA</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Cabrini, MD</last_name>
      <phone>0332 278111</phone>
      <email>l.cabrini@asst-settelaghi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata di Verona</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enrico Polati, MD</last_name>
      <phone>0458122130</phone>
      <email>enrico.polati@univr.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, Fanizza C, Caspani L, Faenza S, Grasselli G, Iapichino G, Antonelli M, Parrini V, Fiore G, Latini R, Gattinoni L; ALBIOS Study Investigators. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 2014 Apr 10;370(15):1412-21. doi: 10.1056/NEJMoa1305727. Epub 2014 Mar 18.</citation>
    <PMID>24635772</PMID>
  </results_reference>
  <results_reference>
    <citation>SAFE Study Investigators, Finfer S, McEvoy S, Bellomo R, McArthur C, Myburgh J, Norton R. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med. 2011 Jan;37(1):86-96. doi: 10.1007/s00134-010-2039-6. Epub 2010 Oct 6.</citation>
    <PMID>20924555</PMID>
  </results_reference>
  <results_reference>
    <citation>Patel A, Laffan MA, Waheed U, Brett SJ. Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality. BMJ. 2014 Jul 22;349:g4561. doi: 10.1136/bmj.g4561. Review. Erratum in: BMJ. 2014;349:g4850.</citation>
    <PMID>25099709</PMID>
  </results_reference>
  <results_reference>
    <citation>Semler MW, Self WH, Rice TW. Balanced Crystalloids versus Saline in Critically Ill Adults. N Engl J Med. 2018 May 17;378(20):1951. doi: 10.1056/NEJMc1804294.</citation>
    <PMID>29768150</PMID>
  </results_reference>
  <results_reference>
    <citation>Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013 Aug 29;369(9):840-51. doi: 10.1056/NEJMra1208623. Review. Erratum in: N Engl J Med. 2013 Nov 21;369(21):2069.</citation>
    <PMID>23984731</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 3, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>December 4, 2019</last_update_submitted>
  <last_update_submitted_qc>December 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Septic Shock</keyword>
  <keyword>Albumin</keyword>
  <keyword>Balanced crystalloids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

